143 results
8-K
EX-10.1
SAVA
Cassava Sciences Inc
22 Mar 19
Termination of a Material Definitive Agreement
4:07pm
. As a direct result of our collective efforts, we successfully moved the entire opioid industry towards safer drug formulations. This alone has saved
8-K
EX-99.1
SAVA
Cassava Sciences Inc
8 Feb 19
Pain Therapeutics Announces Feedback from
4:04pm
of opinion. Abuse deterrence refers to properties that are embedded into an opioid formulation to prevent certain common methods of abuse. During
8-K
EX-99.1
9kwmkt0 b3
4 Oct 18
Regulation FD Disclosure
5:24pm
424B5
upvxi yh5xv0o9
17 Aug 18
Prospectus supplement for primary offering
12:45pm
8-K
EX-99.1
c8ikmijz44emx7npi
6 Aug 18
Other Events
7:00am
8-K
EX-99.1
y8qvph
26 Jul 18
Pain Therapeutics Reports Second Quarter 2018 Financial Results
7:00am
8-K
EX-99.1
2ahiw
9 Jul 18
Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER
6:05am
8-K
EX-99.1
ttkud p780zjf
9 May 18
Pain Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update on REMOXY® ER
7:30am